The Danish Association of Listed Growth Companies has its address on the Copenhagen Stock Exchange and represents the ecosystem of companies that want to be listed on the stock exchange - or have already done so - to raise capital to finance their growth journey. DanCann Pharma A/S is represented in the association by CEO Jeppe Krog Rasmussen, who has recently joined the board.

The ambitious bio-pharma company DanCann Pharma was established in 2018 and was listed in November 2020 on the Spotlight Stock Exchange. Since then, DanCann Pharma has carried out several share issues and capital injections to finance the Company's growth journey with the support of investors.

Jeppe Krog Rasmussen comments:

- I am happy to be able to bring some age-related diversity to an extremely static market of middle-aged men in suits and - hopefully - be a source of inspiration for many young people and appear as a symbol that going public with an IPO is possible, even without +40 years behind you and a long business career on your resumé.

- There are significantly more private investors in Sweden who invest - and especially in smaller growth companies, which we have also experienced in DanCann Pharma. I would very much like to advocate for more Danes to take an interest in Danish growth companies, and thereby share my passion for this. I am proud to contribute to moving the agenda for the Danish growth companies that operate in the listed environment, and at the same time to help ensure better opportunities for the many exciting companies that dream of going public.

- It is a great but also privileged responsibility to represent the many associated companies at such a relatively young age. And it is something that is very close to my heart. At a very young age I invested my very first money on the stock market. Money that would later turn out to be part of the foundation for DanCann Pharma.  

For DanCann Pharma, the CEO's entry into the board of The Danish Association of Listed Growth Companies is a seal of approval for the great work the ambitious Company has completed. With Jeppe Krog Rasmussen as the leading figure, DanCann Pharma has become a company that is noticed - both in the industry and in various investment forums.

Jeppe Krog Rasmussen comments:

- Choosing to go public is certainly not an easy way to go. Especially not in the segment for small and micro-cap companies, which typically require huge sums of capital for the further journey and development in a market that is at times extremely volatile (read: when share prices fluctuate). When your investors call around midnight and ask why the stock is down 10%, for no apparent reason, you need to be prepared and to have your speaking skills in order. Having said that, it is rarely boring, and you quickly become an "adult" in this environment, as a person and as a company. You are subject to a completely different form of control and management in the matter of corporate governance with a board and management, and as a listed company there is thus both a completely different pressure and an increased exposure.

- Personally, I have a strong belief that the best companies are built on the listed platforms, concludes Jeppe Krog Rasmussen.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.